Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
511 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00891475 | Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients | completed | Phase 1 / Phase 2 | 114 | Kidney Cancer Research BureauOTHER | 1 | Feb 13, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 | clinicaltrials |
| NCT00030641 | Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | — | Genta IncorporatedINDUSTRY | 3 | Jan 6, 2014 | clinicaltrials |
| NCT01310816 | A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma | completed | Phase 2 | 105 | Infinity Pharmaceuticals, Inc.INDUSTRY | 13 | Dec 5, 2013 | clinicaltrials |
| NCT01561456 | Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung | completed | Phase 2 | 100 | Axelar ABINDUSTRY | 5 | Dec 5, 2013 | clinicaltrials |
| NCT00431561 | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma | completed | Phase 2 | 141 | Isarna Therapeutics GmbHINDUSTRY | 6 | Dec 3, 2013 | clinicaltrials |
| NCT00320190 | Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib | terminated | Phase 2 | 52 | Bristol-Myers SquibbINDUSTRY | 11 | Oct 30, 2013 | clinicaltrials |
| NCT01038804 | A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer | completed | Phase 2 | 101 | Astellas Pharma IncINDUSTRY | 8 | Sep 18, 2013 | clinicaltrials |
| NCT00964626 | Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer | unknown | Phase 2 | 60 | Russian Academy of Medical SciencesOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01337154 | First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 140 | CytRxINDUSTRY | 6 | Jun 28, 2013 | clinicaltrials |
| NCT00992186 | A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 46 | Centocor Research & Development, Inc.INDUSTRY | 4 | Jun 24, 2013 | clinicaltrials |
| NCT00537381 | An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 2 | 131 | Centocor, Inc.INDUSTRY | 10 | Jun 20, 2013 | clinicaltrials |
| NCT00707889 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | completed | Phase 2 | 159 | AbbVie (prior sponsor, Abbott)INDUSTRY | 14 | May 15, 2013 | clinicaltrials |
| NCT00077857 | A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 9 | May 10, 2013 | clinicaltrials |
| NCT00716534 | Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 145 | AbbVie (prior sponsor, Abbott)INDUSTRY | 6 | Apr 29, 2013 | clinicaltrials |
| NCT00107016 | Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women | completed | Phase 2 | 267 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 4, 2013 | clinicaltrials |
| NCT00777309 | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 167 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 6 | Feb 28, 2013 | clinicaltrials |
| NCT00106353 | Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 1 / Phase 2 | 71 | PfizerINDUSTRY | 7 | Feb 8, 2013 | clinicaltrials |
| NCT00558103 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | completed | Phase 2 | 163 | GlaxoSmithKlineINDUSTRY | 28 | Feb 4, 2013 | clinicaltrials |
| NCT00050141 | Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer | completed | Phase 2 | 121 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 6 | Feb 1, 2013 | clinicaltrials |
| NCT00319254 | Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer | completed | Phase 2 | 75 | PfizerINDUSTRY | 8 | Jan 31, 2013 | clinicaltrials |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | completed | Phase 1 / Phase 2 | 138 | AbbVie (prior sponsor, Abbott)INDUSTRY | 9 | Jan 18, 2013 | clinicaltrials |
| NCT00050440 | Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma | completed | Phase 2 | 50 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 4 | Jan 8, 2013 | clinicaltrials |
| NCT00382720 | Docetaxel and Oxaliplatin in Gastric Cancer | completed | Phase 2 | 275 | SanofiINDUSTRY | 12 | Jan 7, 2013 | clinicaltrials |
| NCT00610714 | AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer(OVERT-1) | completed | Phase 2 | 211 | AstraZenecaINDUSTRY | 12 | Dec 18, 2012 | clinicaltrials |
| NCT01231802 | Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer | unknown | Phase 2 | 140 | Adherex Technologies, Inc.INDUSTRY | 2 | Jul 17, 2012 | clinicaltrials |
| NCT01290406 | BEZ235 Trial in Patients With Advanced Endometrial Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 21, 2012 | clinicaltrials |
| NCT00499265 | Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 95 | Heidelberg Pharma AGINDUSTRY | 6 | Mar 29, 2012 | clinicaltrials |
| NCT00149214 | Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens | completed | Phase 2 | 257 | Eli Lilly and CompanyINDUSTRY | 4 | Mar 21, 2012 | clinicaltrials |
| NCT00558363 | ARTS - AVODART After Radical Therapy For Prostate Cancer Study(ARTS) | completed | Phase 2 | 294 | GlaxoSmithKlineINDUSTRY | 9 | Mar 21, 2012 | clinicaltrials |
| NCT00322348 | Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women | completed | Phase 2 | 98 | AstraZenecaINDUSTRY | 3 | Jan 24, 2011 | clinicaltrials |
| NCT00401323 | Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 568 | SanofiINDUSTRY | 20 | Jan 20, 2011 | clinicaltrials |
| NCT00268892 | Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 278 | Ferring PharmaceuticalsINDUSTRY | 10 | Dec 24, 2010 | clinicaltrials |
| NCT00116753 | A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer | completed | Phase 2 | 460 | Ferring PharmaceuticalsINDUSTRY | 11 | Dec 10, 2010 | clinicaltrials |
| NCT00571675 | A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 220 | Ascenta TherapeuticsINDUSTRY | 2 | Nov 9, 2010 | clinicaltrials |
| NCT00544960 | A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 106 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 27, 2010 | clinicaltrials |
| NCT00397293 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 24, 2010 | clinicaltrials |
| NCT01176552 | Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer | completed | Phase 2 | 35 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT01182142 | Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients | completed | Phase 2 | 51 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT00415168 | Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer | completed | Phase 2 | 53 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 17, 2010 | clinicaltrials |
| NCT00103844 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 32 | Aug 10, 2010 | clinicaltrials |
| NCT00190671 | A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients | completed | Phase 1 / Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 6 | Nov 20, 2009 | clinicaltrials |
| NCT00191815 | Combination Chemotherapy for Metastatic Breast Cancer | completed | Phase 2 | 70 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 11, 2009 | clinicaltrials |
| NCT00770354 | Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer | terminated | Phase 2 | 110 | Antisoma ResearchINDUSTRY | 1 | Aug 10, 2009 | clinicaltrials |
| NCT00034164 | Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer | completed | Phase 2 | 52 | Achieve Life SciencesINDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00096668 | Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer | completed | Phase 2 | 47 | Achieve Life SciencesINDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00591188 | Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens | completed | Phase 2 | 49 | Kidney Cancer Research BureauOTHER | 1 | May 1, 2009 | clinicaltrials |
| NCT00191334 | Gemcitabine in Ovarian Cancer | completed | Phase 2 | 50 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 27, 2009 | clinicaltrials |
| NCT00116610 | Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer | completed | Phase 2 | 75 | Poniard PharmaceuticalsINDUSTRY | 3 | Jan 21, 2009 | clinicaltrials |
| NCT00448734 | A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer | unknown | Phase 1 / Phase 2 | 95 | Poniard PharmaceuticalsINDUSTRY | 1 | Jan 21, 2009 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials